Cannabinoids for Epidermolysis Bullosa: Early Signals, Limited Evidence
Epidermolysis bullosa (EB) can turn ordinary friction into blisters, open wounds and severe pain. The inherited disorder affects the proteins that hold layers of skin together, and symptoms may also involve mucous membranes. Because there is no universal cure, care typically centers on protecting fragile skin, treating wounds and infections, and managing pain and itching. The National Institute of Arthritis and Musculoskeletal and Skin Diseases’ treatment guidance outlines the supportive approach currently used for EB.
That treatment gap has led some patients and researchers to investigate cannabinoid-based medicines, including cannabidiol (CBD) and tetrahydrocannabinol (THC). The evidence, however, remains preliminary. Much of the interest comes from laboratory research, individual experiences and small, uncontrolled studies—not from large clinical trials showing that cannabinoids treat the underlying disease.
The most directly relevant early report was a 2018 case report published in the British Journal of Dermatology. Researchers described three people with EB who received pharmaceutical-grade cannabinoid medicine containing both THC and CBD under the tongue. All three reported lower pain scores, less itching and reduced use of other analgesics. These results are encouraging, but three cases cannot establish how effective the treatment is, whether it works better than standard care or which patients are most likely to benefit.
A separate 2018 report described three pediatric patients who independently used topical CBD oil. The patients’ families reported improvements in pain, itching, skin condition and wound healing, without apparent adverse effects. Such observations can help generate research questions, but they are especially vulnerable to placebo effects, changes in wound care and the natural fluctuations of EB. They also do not establish the safety or effectiveness of unregulated products.
Reviews of the skin’s endocannabinoid system have proposed several possible mechanisms for cannabinoid treatment. CBD has been studied for potential anti-inflammatory, antioxidant and pain-modulating effects, while THC acts more directly on cannabinoid receptors and can produce psychoactive effects. Laboratory findings and research in other skin conditions may explain why cannabinoids are being considered, but they should not be presented as proof that a cannabinoid cream will heal EB wounds or prevent blistering. The 2020 review of CBD in skin health and disorders also emphasized the need for better clinical evidence.
An investigator-initiated study of a 3% CBD cream was registered as a phase II/III trial, but the ClinicalTrials.gov record shows that it was withdrawn before enrolling participants. That means it did not provide the clinical results originally anticipated.
Research has since expanded to other cannabinoids. InMed Pharmaceuticals reported results in 2023 from a company-sponsored phase II study of INM-755, a topical cannabinol (CBN) cream. The trial enrolled 19 people, with 18 included in the efficacy analysis. The company reported clinically meaningful itch improvement in some participants, but the prespecified analysis for non-wound itch was not statistically significant compared with the control cream. Too few participants had pain or wound-related symptoms for those outcomes to be meaningfully analyzed. The findings are therefore best regarded as exploratory; the company’s published trial announcement is not a substitute for an independent, peer-reviewed clinical report.
For now, cannabinoid-based medicines may offer a possible avenue for relieving pain or itching for some people with EB, but they are not an established treatment or a cure. Anyone considering CBD, THC or another cannabinoid—particularly for open wounds—should discuss the product and formulation with an EB specialist. Product concentration, contamination, drug interactions, psychoactive effects and absorption through damaged skin all require careful consideration. Larger, well-controlled trials are still needed to determine which cannabinoids, if any, provide reliable benefits and whether those benefits outweigh the risks.
